Epratuzumab - redOrbit

News - Epratuzumab

Epratuzumab Phase IIb Data Presented at ACR Show Pipeline Drug had Positive Effect in Patients Suffering From Moderate to Severe Systemic Lupus Erythematosus

2010-11-09 07:05:00

ATLANTA, Nov. 9, 2010 /PRNewswire/ -- UCB (EURONEXT: UCB) and U.S. based partner Immunomedics Inc.

New Data Presented from EMBLEM(TM) Study for Pipeline Drug Epratuzumab for Patients Suffering from Moderate to Severe Systemic Lupus Erythematosus

2010-06-16 08:30:00

ATLANTA, June 16 /PRNewswire-FirstCall/ -- UCB (Euronext: UCB) and Immunomedics, Inc. (Nasdaq: IMMU) announced new lupus drug candidate, epratuzumab, provided a significant reduction in disease activity in patients with moderate to severe active systemic lupus erythematosus (SLE).

Immunomedics to Present At Lazard Capital Markets Fifth Annual Healthcare Conference

2008-11-11 09:00:47

MORRIS PLAINS, N.J., Nov. 11, 2008 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that Gerard G.

Study Results Show Epratuzumab Provided Clinically Meaningful Reduced Disease Activity in Patients With Lupus

2008-10-27 15:00:09

SAN FRANCISCO, Oct.

Immunomedics Announces U.S. Patents Awarded for CD20 Antibody, Veltuzumab, and Reagents Used in Pretargeted Imaging and Therapies

2008-10-14 09:00:11

MORRIS PLAINS, N.J., Oct. 14, 2008 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, announced that U.S.

More News (73 articles) »

News - Epratuzumab

Breaking News

Streaming Video

Images and Photos

Space Exploration

Science and Research

Technology

My Health